In Belgium, a royal decree of June 2015 prohibits pharmacists from supplying magistral preparations - prescription drugs made in the pharmacy itself - containing THC. Only the drug Sativex, which contains both THC and CBD, is permitted for MS patients under certain conditions.
However, the KB also prohibited preparations with CBD, such as cannabis oil, because trace amounts of THC always occur. "Such a prohibition does not seem to be the intention of the KB," it says in the circular from the FAMHP. The agency therefore now allows "raw materials such as cannabidiol with trace amounts of THC" to be used for pharmaceutical compounding if the patient's exposure to THC does not exceed 1 microgram per kilogram of body weight per day. Pharmacists must be "vigilant for side effects" and "acquire the necessary knowledge," it says.
